Ocugen, Inc.
(NASDAQ : OCGN)

( )
OCGN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -4.36%352.430.0%$5529.05m
BNTXBioNTech SE -2.97%351.740.0%$1554.09m
NVAXNovavax, Inc. 7.56%208.6378.2%$1149.83m
AMGNAmgen, Inc. -2.26%198.881.4%$591.30m
LGVNLongeveron Inc. 0.04%26.260.0%$511.78m
GILDGilead Sciences, Inc. -2.44%68.931.0%$497.91m
REGNRegeneron Pharmaceuticals, Inc. -2.73%636.532.7%$490.45m
VRTXVertex Pharmaceuticals, Inc. -1.67%186.941.9%$375.32m
SNSSSunesis Pharmaceuticals, Inc. 0.88%4.610.7%$322.26m
ILMNIllumina, Inc. -1.48%365.333.3%$311.28m
OCGNOcugen, Inc. -1.40%6.340.0%$293.70m
BIIBBiogen, Inc. -0.16%235.741.8%$289.61m
EXASEXACT Sciences Corp. -1.39%85.3718.0%$167.68m
INCYIncyte Corp. -3.77%67.722.4%$165.57m
BMRNBioMarin Pharmaceutical, Inc. -1.27%86.294.2%$144.64m

Company Profile

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.